Volumetric Analysis of Bone Following Jaw Cysts Enucleation With and Without Alb-PRF
NCT ID: NCT05658900
Last Updated: 2022-12-21
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
20 participants
INTERVENTIONAL
2022-05-19
2023-03-09
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Enucleation with albumin PRF
Enucleation with albumin PRF
The protocol that will be used in the preparation of albumin PRF
1. A sample of venous blood, at ten milliliters, at least will be drawn from the patient in a sterile centrifuge tube.
2. The venous blood sample will be centrifuged at 700 g for 8 minutes.
\* Betadine: Povidone-iodine, 7.5% (0.75% available iodine), Purdue Products L.P
3. The platelet-poor plasma layer will be taken and heated at uniform temperature 75 celsius for 10 minutes in a thermostatic water bath incubator to denature albumin protein forming albumin gel.
4. Once the albumin gel is cooled, to room temperature for 10 minutes, it will be mixed with the buffy coat layer of PRF using 3 way stop cock and 2 plastic syringes with Luer lock to obtain albumin PRF then leave it in the dappen dish for 5 minutes.
Enucleation without albumin PRF
Enucleation without albumin PRF
The full-thickness mucoperiosteal flap will be performed using blade no. 15 and Bard- Parker handles extending one tooth anterior and one tooth posterior to the cystic cavity.
The mucoperiosteal flap will be reflected using the periosteal elevator to expose the bone.
Removal of the overlying bone to expose the cystic lesion. Enucleation of the cyst.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Enucleation with albumin PRF
The protocol that will be used in the preparation of albumin PRF
1. A sample of venous blood, at ten milliliters, at least will be drawn from the patient in a sterile centrifuge tube.
2. The venous blood sample will be centrifuged at 700 g for 8 minutes.
\* Betadine: Povidone-iodine, 7.5% (0.75% available iodine), Purdue Products L.P
3. The platelet-poor plasma layer will be taken and heated at uniform temperature 75 celsius for 10 minutes in a thermostatic water bath incubator to denature albumin protein forming albumin gel.
4. Once the albumin gel is cooled, to room temperature for 10 minutes, it will be mixed with the buffy coat layer of PRF using 3 way stop cock and 2 plastic syringes with Luer lock to obtain albumin PRF then leave it in the dappen dish for 5 minutes.
Enucleation without albumin PRF
The full-thickness mucoperiosteal flap will be performed using blade no. 15 and Bard- Parker handles extending one tooth anterior and one tooth posterior to the cystic cavity.
The mucoperiosteal flap will be reflected using the periosteal elevator to expose the bone.
Removal of the overlying bone to expose the cystic lesion. Enucleation of the cyst.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients with no gender predilection that agreed to present for follow-up visits for a minimum postoperative period of 6 months.
* Cystic lesion that requires removal under local or general anaesthesia.
Exclusion Criteria
* Patients with history of chemotherapy or radiotherapy.
* Patients with low level of platelet count.
* Patients with anticoagulant therapy.
* Patients who are unable to attend follow up appointments
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hams Hamed Abdelrahman
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Hams Hamed Abdelrahman
Assistant lecturer of DPH and Clinical statistician
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Outpatient Clinic of Oral and Maxillofacial Surgery Department, Faculty of Dentistry, Alexandria University, Egypt
Alexandria, Azarita, Egypt
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Faculty of Dentistry
Role: primary
References
Explore related publications, articles, or registry entries linked to this study.
Shokry MMEM, Melek LNF, Amer TA. Three-dimensional volumetric analysis of bone regeneration following jaw cyst enucleation with and without an autologous albumin gel-platelet-rich fibrin mixture (Alb-PRF): a randomized controlled clinical trial. BMC Oral Health. 2025 May 8;25(1):693. doi: 10.1186/s12903-025-06027-w.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Cysts_2022
Identifier Type: -
Identifier Source: org_study_id